Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
Links relacionados
- Similares em SciELO
Compartilhar
Revista Peruana de Medicina Experimental y Salud Publica
versão impressa ISSN 1726-4634
Resumo
GUTIERREZ-AGUADO, Alfonso. Cost- utility of the vaccine against the human papiloma virus in peruvian women. Rev. perú. med. exp. salud publica [online]. 2011, vol.28, n.3, pp.416-425. ISSN 1726-4634.
Objetives. To estimate the cost-utility of the vaccine against the Human Papiloma Virus (HPV) in peruvian women after the application of the vaccine at 10 years of age. Materials and methods. A cost-utility analysis was performed using the Markov´s hidden model in a hypothetical cohort of peruvian women, based on the information on epidemiological parameters, costs associated to uterine cervical cancer (UCC) and the efficacy and costs of the vaccine against the HPV. The vaccination costs were estimated from the Peruvian Ministry of Health perspective and were compared against the quality-adjusted life years (QALYs), using a discount rate of 5%. Results. The annual cost of the vaccination was USD 16861,490, for the Papanicoau screening it was USD 3060,793 and the costs associated to the UCC were USD 15580,000. The incremental cost utility ratio (ICUR) was 6,775 USD/QALY. Conclusions. Vaccination against HPV can be cost-utility compared to not vaccinating.
Palavras-chave : Papillomavirus vaccines; Uterine cervical neoplasms; Inmunization; Costs and cost analysis.